Glejak: badanie obserwacyjne

Gdzie prowadzone jest badanie

Ośrodki prowadzące badanie w Polsce (1), alfabetycznie według miejscowości:

• Department of Neurosurgery of Medical Univeristy of Warsaw Rekrutuje
  WarszawaKontakt

Więcej badań w tych miastach:

• Warszawa

Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.

Cel badania

Opis z rejestru (w języku angielskim):

Cerebrospinal fluid is a clear fluid that surrounds and protects the brain. During surgery for brain tumors, neurosurgeons often need to open the covering of the brain (the dura) to reach the tumor. At the end of the operation, this covering is carefully closed again. In some cases, the closure might not be completely adequate leading to cerebrospinal fluid leak. This leakage may collect under the scalp or flow out through the surgical wound. When this happens, the surgical wound may not heal properly, and the risk of infection can increase. These complications can delay recovery and may postpone additional treatments, such as radiotherapy or chemotherapy, that are often needed after brain tumor surgery. Although cerebrospinal fluid leakage is less common after supratentorial craniotomy (surgery on the upper part of the brain) than after other types of brain surgery, it remains a challenging complication and has not been well studied in this group of patients. The aim of this study is to determine how often cerebrospinal fluid leakage occurs after supratentorial craniotomy for intracranial tumors, identify factors that increase the risk of leakage, and evaluate how these leaks are managed. Understanding these factors may help reduce the occurrence of cerebrospinal fluid leakage and improve postoperative recovery in the future.

Kryteria udziału

Kryteria w języku angielskim, tak jak w rejestrze.

To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.

Inne badania: glejak

Rekrutuje

Badanie kliniczne

TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)

Miasta: BydgoszczWiek: od 18 latSponsor: Prof. Franciszek Lukaszczyk Memorial Oncology Center

Rekrutuje

Badanie kliniczne

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)

Miasta: WarszawaWiek: 18-80 latSponsor: Medical University of Warsaw

Rekrutuje

Badanie kliniczne

Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures

Miasta: WarszawaWiek: od 18 latSponsor: Medical University of Warsaw

Rekrutuje

Badanie kliniczne

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression

Miasta: WarszawaWiek: 18-80 latSponsor: Medical University of Warsaw

RekrutujeFaza II

Badanie fazy II leku trametinib

Multicenter, open label study using molecularly determined targeted therapies in children 3-18 years of age with DIPG (diffuse intrinsic pontine glioma- DIPG)- DIPGen

Badane leki: trametinib

Miasta: Katowice, WarszawaWiek: do 64 latSponsor: Instytut Pomnik Centrum Zdrowia Dziecka

RekrutujeFaza III

Badanie fazy III leku temozolomide i pembrolizumab

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Badane leki: temozolomidepembrolizumab+4

Miasta: Bydgoszcz, Gliwice, ŁódźWiek: od 18 latSponsor: Novocure GmbH

Wszystkie badania: glejak